Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong.

Andrea On Yan LukTerry C F YipXinge ZhangAlice Pik Shan KongVincent Wai-Sun WongRonald Ching Wan MaGrace Lai-Hung Wong

Published in: BMJ open (2021)

Users of metformin and DPP-4 inhibitors had fewer adverse outcomes from COVID-19 compared with non-users, whereas insulin and sulphonylurea might predict a worse prognosis.

Keyphrases

coronavirus disease
sars cov
glycemic control
type diabetes
blood glucose
metabolic syndrome
cardiovascular risk factors
insulin resistance
weight loss